Intas is betting on an antibody booster shot to fight the virus.
Dear Balbir Singh,
When the entire mankind is making a concerted effort to rein in the pandemic, even baby steps matter. As the race to come up with the first effective vaccine for Covid-19 is on, an Ahmedabad-based mid-sized pharma company is flexing its muscles to dare the marauding coronavirus. And the best part: it expects no commercial gains if it succeeds. Hope you didn’t miss our story on Intas Pharmaceuticals which explains why the company is bullish on an unproven therapy.
Here’s a collection of some of our most engaging stories:
Intas takes an antibody shot at the virus
Intas is betting on an antibody booster shot to fight the virus. The best part: it’s not for profit.
India’s Covid-19 cases may have peaked in September
Viral impact: India logs the highest confirmed cases in September, but the worst may be over
Pandemic puts impulse buying on a pause
‘Impulse buying declined’: how the pandemic has put a pause on consumers’ urge to splurge
Maruti drives ahead with its retail twins
How does Maruti drive ahead of its rivals even in a pandemic? Ask its retail twins, Nexa and Arena.
Inside the recovery underway at Dr. Reddy’s
A recovery is underway at Dr. Reddy’s: results from US-business tweaks and CEO’s hawk eye on returns.
We hope you enjoy the selection. Do let us know what more you’d like to read in our weekend editions.
Regards,
ET Prime Team